Skip to Main Content

Author Details

Jeffrey W Tyner
Oregon Health & Science University School of Medicine
2002
201
53
PMIDPaper TitleJournal TitlePublished Year
36041918Chasing leukemia differentiation through induction therapy, relapse and transplantation.Blood Rev2023
37756525Germ line variant GFI1-36N affects DNA repair and sensitizes AML cells to DNA damage and repair therapy.Blood2023
37698624Clinical Correlates of Venetoclax-Based Combination Sensitivities to Augment Acute Myeloid Leukemia Therapy.Blood Cancer Discov2023
37509251Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia.Cancers (Basel)2023
37607920Favorable outcomes of NPM1<sup>mut</sup> AML patients are due to transcriptional inactivation of FOXM1, presenting a new target to overcome chemoresistance.Blood Cancer J2023
37815132The FLT3<sup>N701K</sup> mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.Am J Hematol2023
37087441Treatment for ovarian clear cell carcinoma with combined inhibition of WEE1 and ATR.J Ovarian Res2023
37182843CDK12/13 dual inhibitors are potential therapeutics for acute myeloid leukemia.Br J Haematol2023
36976323Disruption of the MYC Superenhancer Complex by Dual Targeting of FLT3 and LSD1 in Acute Myeloid Leukemia.Mol Cancer Res2023
37361575Immune cell proportions correlate with clinicogenomic features and <i>ex vivo</i> drug responses in acute myeloid leukemia.Front Oncol2023
37398007Ribosomal protein control of hematopoietic stem cell transformation through direct, non-canonical regulation of metabolism.bioRxiv2023
36626250Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures.Blood2023
36441905Comparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Blood Adv2023
33375770Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.Haematologica2022
35732831The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms.Leukemia2022
35343367Functional proteomics of patient derived head and neck squamous cell carcinoma cells reveal novel applications of trametinib.Cancer Biol Ther2022
35499387Luxeptinib (CG-806) Targets FLT3 and Clusters of Kinases Operative in Acute Myeloid Leukemia.Mol Cancer Ther2022
36551626Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia.Cancers (Basel)2022
35868306Integrative analysis of drug response and clinical outcome in acute myeloid leukemia.Cancer Cell2022
36307214Comprehensive molecular characterization of a rare case of Philadelphia chromosome-positive acute myeloid leukemia.Cold Spring Harb Mol Case Stud2022
35896960Proteomic and phosphoproteomic measurements enhance ability to predict ex vivo drug response in AML.Clin Proteomics2022
35296646Dual BTK/SYK inhibition with CG-806 (luxeptinib) disrupts B-cell receptor and Bcl-2 signaling networks in mantle cell lymphoma.Cell Death Dis2022
35195258Understanding Drug Sensitivity and Tackling Resistance in Cancer.Cancer Res2022
35078224Associating drug sensitivity with differentiation status identifies effective combinations for acute myeloid leukemia.Blood Adv2022
34780648MS4A3 promotes differentiation in chronic myeloid leukemia by enhancing common β-chain cytokine receptor endocytosis.Blood2022
34482403Identification and prioritization of myeloid malignancy germline variants in a large cohort of adult patients with AML.Blood2022
32898857Concomitant use of a dual Src/ABL kinase inhibitor eliminates the in vitro efficacy of blinatumomab against Ph+ ALL.Blood2021
33707228DNA methylation epitypes highlight underlying developmental and disease pathways in acute myeloid leukemia.Genome Res2021
33563661Matched Targeted Therapy for Pediatric Patients with Relapsed, Refractory, or High-Risk Leukemias: A Report from the LEAP Consortium.Cancer Discov2021
33560385Antileukemic efficacy of a potent artemisinin combined with sorafenib and venetoclax.Blood Adv2021
34496019A novel activating JAK1 mutation in chronic eosinophilic leukemia.Blood Adv2021
34568834Monocytic differentiation and AHR signaling as Primary Nodes of BET Inhibitor Response in Acute Myeloid Leukemia.Blood Cancer Discov2021
34504101TNK1 is a ubiquitin-binding and 14-3-3-regulated kinase that can be targeted to block tumor growth.Nat Commun2021
34222745<i>Ex Vivo</i> Analysis of Primary Tumor Specimens for Evaluation of Cancer Therapeutics.Annu Rev Cancer Biol2021
34302041Bayesian multi-source regression and monocyte-associated gene expression predict BCL-2 inhibitor resistance in acute myeloid leukemia.NPJ Precis Oncol2021
34233959Pharmacologic Targeting of Mcl-1 Induces Mitochondrial Dysfunction and Apoptosis in B-Cell Lymphoma Cells in a <i>TP53-</i> and <i>BAX-</i>Dependent Manner.Clin Cancer Res2021
34233449Aurora A kinase as a target for therapy in <i>TCF3-HLF</i> rearranged acute lymphoblastic leukemia.Haematologica2021
34171263The AML microenvironment catalyzes a stepwise evolution to gilteritinib resistance.Cancer Cell2021
32366937ERBB2/HER2 mutations are transforming and therapeutically targetable in leukemia.Leukemia2020
31844143Insights on mechanisms of clonal evolution in chronic neutrophilic leukemia on ruxolitinib therapy.Leukemia2020
31880950Efficacy of Ruxolitinib in Patients With Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia.J Clin Oncol2020
32094466Simultaneous kinase inhibition with ibrutinib and BCL2 inhibition with venetoclax offers a therapeutic strategy for acute myeloid leukemia.Leukemia2020
33123685Integrated analysis of patient samples identifies biomarkers for venetoclax efficacy and combination strategies in acute myeloid leukemia.Nat Cancer2020
32988967AZD4320, A Dual Inhibitor of Bcl-2 and Bcl-x<sub>L</sub>, Induces Tumor Regression in Hematologic Cancer Models without Dose-limiting Thrombocytopenia.Clin Cancer Res2020
32843430Functional genomic analysis identifies drug targetable pathways in invasive and metastatic cutaneous squamous cell carcinoma.Cold Spring Harb Mol Case Stud2020
32754299Genomic markers of midostaurin drug sensitivity in FLT3 mutated and FLT3 wild-type acute myeloid leukemia patients.Oncotarget2020
32513686Reversible suppression of T cell function in the bone marrow microenvironment of acute myeloid leukemia.Proc Natl Acad Sci U S A2020
32482750Keys to drug sensitivity from updated functional work flows.Haematologica2020
32315394Discovery and characterization of targetable NTRK point mutations in hematologic neoplasms.Blood2020
30642575Predicting response to BET inhibitors using computational modeling: A BEAT AML project study.Leuk Res2019
  • 1 - 50 of 201

Recommended Authors

Veronique Litalien
Walter and Eliza Hall Institute of Medical Research
Career Start Year 2016
Number of shared co-authors 2
Fiorella Schischlik
National Cancer Institute, National Institutes of Health
Career Start Year 2013
Number of shared co-authors 1
Bartlomiej Przychodzen
Vanda Pharmaceuticals Inc.
Career Start Year 2010
Number of shared co-authors 14
Stuart J Blakemore
Center for Molecular Medicine Cologne (CMMC), University of Cologne
Career Start Year 2010
Number of shared co-authors 4
Anagha Deshpande
Sanford Burnham Prebys Medical Discovery Institute
Career Start Year 2009
Number of shared co-authors 1
Lina Benajiba
Universite de Paris, Inserm CIC 1427
Career Start Year 2009
Number of shared co-authors 7
Amanda Winters
University of Colorado School of Medicine
Career Start Year 2008
Number of shared co-authors 12
Paulo Vidal Campregher
Hospital Israelita Albert Einstein
Career Start Year 2007
Number of shared co-authors 2
Alexandre Puissant
Universite de Paris, INSERM, CNRS
Career Start Year 2007
Number of shared co-authors 11
Courtney D DiNardo
UT MD Anderson Cancer Center
Career Start Year 2007
Number of shared co-authors 35
Jean-Baptiste Micol
INSERM U7, Universite Paris-Saclay
Career Start Year 2004
Number of shared co-authors 16
Rhonda E Ries
Clinical Research Division, Fred Hutchinson Cancer Research Center
Career Start Year 2003
Number of shared co-authors 20
Christopher C Porter
Emory University School of Medicine
Career Start Year 2003
Number of shared co-authors 8
Giovanni Roti
University of Parma
Career Start Year 2003
Number of shared co-authors 10
Anna L Brown
Adelaide Medical School, University of Adelaide
Career Start Year 2003
Number of shared co-authors 17
Thomas Ernst
Universitatsklinikum Jena
Career Start Year 2002
Number of shared co-authors 10
Jeffery M Klco
St. Jude Children's Research Hospital
Career Start Year 2000
Number of shared co-authors 17
Rose Hurren
Princess Margaret Cancer Centre
Career Start Year 1999
Number of shared co-authors 4
Lukas D Wartman
Washington University School of Medicine in St. Louis
Career Start Year 1998
Number of shared co-authors 5
Brian J P Huntly
University of Cambridge
Career Start Year 1996
Number of shared co-authors 18
Yongjin Li
Mayo Clinic
Career Start Year 1995
Number of shared co-authors 15
Timothy A Graubert
Massachusetts General Hospital
Career Start Year 1993
Number of shared co-authors 22
Mark J Levis
Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University
Career Start Year 1992
Number of shared co-authors 17
Michael W Becker
James P. Wilmot Cancer Institute, University of Rochester Medical Center Rochester
Career Start Year 1992
Number of shared co-authors 12
Scott A Armstrong
Boston Children's Hospital
Career Start Year 1990
Number of shared co-authors 28
Todd R Golub
Broad Institute of MIT and Harvard
Career Start Year 1989
Number of shared co-authors 31
Aaron D Schimmer
Princess Margaret Cancer Centre
Career Start Year 1989
Number of shared co-authors 15
Suzanne Kamel-Reid
Toronto General Hospital, University Health Network, University of Toronto
Career Start Year 1988
Number of shared co-authors 11
Marcela Gronda
Princess Margaret Cancer Centre
Career Start Year 1985
Number of shared co-authors 3
Neil P Shah
University of California San Francisco
Career Start Year 1985
Number of shared co-authors 28

Collaborators

Brian J Druker
Oregon Health & Science University
Co-authored papers 95
Shannon K McWeeney
Oregon Health & Science University, University of California Berkeley
Co-authored papers 44
Marc M Loriaux
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 40
Christopher A Eide
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 39
Cristina E Tognon
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 30
Michael W Deininger
University of Utah Huntsman Cancer Institute
Co-authored papers 30
Daniel Bottomly
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 29
Anupriya Agarwal
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 27
Bill H Chang
Oregon Health and Science University
Co-authored papers 26
Elie Traer
Oregon Health & Science University
Co-authored papers 22
Beth Wilmot
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 20
Julia E Maxson
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 20
Thomas O'Hare
Huntsman Cancer Institute, University of Utah
Co-authored papers 16
Stephen E Kurtz
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 16
Nicola Long
Oregon Health and Science University
Co-authored papers 14
Kim-Hien T Dao
Astex Pharmaceuticals
Co-authored papers 14
Andy Kaempf
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 12
Jason Gotlib
Stanford University School of Medicine
Co-authored papers 11
Robert H Collins
University of Texas Southwestern Medical Center
Co-authored papers 11
Haijiao Zhang
Oregon Health & Science University, Knight Cancer Institute
Co-authored papers 10
Samuel B Luty
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 10
Kevin Watanabe-Smith
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 10
Stephen E Spurgeon
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 10
Jennifer Dunlap
Oregon Health & Science University
Co-authored papers 9
Samantha L Savage
Knight Cancer Institute, Oregon Health & Science University
Co-authored papers 9
Melissa L Abel
National Cancer Institute, National Institutes of Health
Co-authored papers 8
David K Edwards
Exact Sciences Corporation
Co-authored papers 8
Michael J Holtzman
Co-authored papers 8
Tamilla Nechiporuk
Knight Cancer Institute, Oregon Health and Science University
Co-authored papers 8
Daniel A Pollyea
University of Colorado Division of Hematology
Co-authored papers 8
Release 1.2